The effect of rAd-p53+cisplatin on gastric cancer cell growth and KAI1/CD82 expression

Objective To investigate the effects of rAd-p53 and cisplatin (DDP)alone or in combination on the proliferation, apoptosis, and KAI1/CD82 protein expression of human gastric cancer SGC7901 cells. Methods SGC7901 cells were treated with rAd-p53, DDP, or their combination for 24,48, and 72 hours. The proliferation activity of SGC7901 cells was measured using the CCK-8 assay. Apoptosis rates were determined by flow cytometry, and the expression of KAI1/CD82 protein was detected by immunohistochemistry. Results Both rAd-p53 and DDP alone, as well as their combination, inhibited the proliferation of SGC7901 cells in a dose-and time-dependent manner. The proliferation inhibition rate of the combination group was significantly higher than that of the single-agent groups, with statistically significant differences compared to the negative control group(P<0.05).After 48 hours of treatment with rAd-p53,DDP,or their combination, the apoptosis rates were 36.94%±0.78%,28.79%±2.37%,and 69.26%±0.63%,respectively,all of which were significantly higher than that of the negative control group(16.72%±1.54%,P<0.05).Both rAd-p53 and DDP alone, as well as their combination, upregulated the expression of KAI1/CD82 protein, with the combination group showing the most significant increase. Conclusion Both rAd-p53 and DDP alone, as well as their combination, can inhibit the growth of gastric cancer SGC7901 cells and induce apoptosis. The combination of the two drugs enhances the inhibitory effect on gastric cancer cells. rAd-p53 may induce apoptosis in SGC7901 cells by upregulating the expression of KAI1/CD82, thereby enhancing the antitumor effect of DDP.